StockNews.AI
BHVN
StockNews.AI
21 days

Shareholders of Biohaven Ltd. Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVN

1. Biohaven Ltd. faces a class action securities lawsuit alleging fraud. 2. Claims include overstating candidate drug efficacy and regulatory prospects. 3. Investors may recover losses incurred from March 2023 to May 2025. 4. Law firm Levi & Korsinsky leads the litigation for affected investors. 5. Participation in the class action comes at no cost to investors.

5m saved
Insight
Article

FAQ

Why Bearish?

The allegations of fraud and overstated efficacy can significantly undermine investor confidence, leading to price declines. Historical instances show companies facing similar lawsuits often experience stock price drops during litigation periods.

How important is it?

The lawsuit is central to investors' confidence and the company's financial stability, directly impacting stock performance. Given the ongoing nature of the accusations, it heightens the importance for stakeholders.

Why Long Term?

The ongoing lawsuit may result in prolonged uncertainty about BHVN's business prospects, affecting its valuation over time. Such cases can take years to resolve, which may leave lasting impressions on investor sentiment.

Related Companies

BIIBVRTXEXAS
, /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biohaven Ltd. investors who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=158417&wire=4 BHVN investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) The company's product candidate, troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times. WHAT'S NEXT? If you suffered a loss in Biohaven Ltd. during the relevant time frame, you have until September 12, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004[email protected]Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News